Table 3.

COMPASS 31 total score and subdomains

COMPASS 31	PCS/non-ME/CFS (n = 23)		PCS/ME/CFS (n = 19)		non-COVID ME/CFS (n = 19)
	Median	Range	Median	Range	Median	Range
Total	26.8	(2.5–54.0)	39.4	(7.1–62.2)	41.0	(7.8–66.4)
Orthostasis	16.0	(0–40)	24.0	(0–40)	28.0	(0–40)
Vasomotor	0.0	(0–4.2)	0.0	(0–4.2)	0.0	(0–4)
Secretomotor	2.1	(0–10.7)	4.3	(0–12.9)	4.3	(0–12.9)
Gastrointestinal	6.3	(0–16.1)	6.3	(0–15.2)	8.9	(3.6–14.2)
Bladder	0.0	(0–3.3)	0.0	(0–3.3)	1.1	(0–3.3)
Pupillomotor	1.3	(0–3.0)	1.7	(0–3.3)	1.8	(0–3.3)

Autonomic symptoms were assessed by COMPASS 31 questionnaire (Composite Autonomic Symptom Score 31) in PCS cohorts and non-COVID-ME/CFS, considering the total score (0–100) and the scores of the six subdomains orthostasis (0–40), vasomotor (0–5), secretomotor (0–15), gastrointestinal (0–25), bladder (0–10) and pupillomotor (0–5). Data were analyzed using nonparametric all-pairs Dunn-type multiple contrast tests. The p values were adjusted for multiplicity across domains with the Benjamini-Hochberg (BH) correction, none of the comparisons remained significant. Source data are provided as a Source Data file.

PCS/non-ME/CFS post-COVID-19 syndrome/non-myalgic encephalomyelitis/chronic fatigue syndrome, PCS/ME/CFS post-COVID-19 syndrome/myalgic encephalomyelitis/chronic fatigue syndrome, non-COVID ME/CFS non-COVID-19 myalgic encephalomyelitis/chronic fatigue syndrome.